Protocol for Pharmacist-Led Continuous Glucose Monitoring in Prediabetes
بروتوكول للمراقبة المستمرة للجلوكوز بقيادة الصيدلي لمرحلة ما قبل السكري
Journal: JMIR research protocols
University: PubMed
Study Type: cohort
Evidence Level: preliminary
Participants: 40
Published:
⚠️ Warning: This is a preliminary study (animal/cell) and has not been proven in humans.
30-Second Summary
This protocol outlines a planned study to evaluate the impact of pharmacist-led continuous glucose monitoring (CGM) on adults with prediabetes. The study aims to compare a prospective CGM cohort with a retrospective usual-care cohort over 12 weeks.
1-Minute Summary
Prediabetes is a critical period where interventions might influence the progression to type 2 diabetes. This study protocol describes a prospective cohort study that will investigate the effects of pharmacist-led continuous glucose monitoring (CGM) combined with diabetes self-management education. The planned study will include 40 adults, comparing 20 participants using CGM for 12 weeks against 20 matched retrospective controls. Researchers aim to measure changes in hemoglobin A1c, behavioral outcomes, and safety, though no participants have been enrolled and no results are currently available.
3-Minute Summary
The provided text is an abstract for a study protocol titled 'Pharmacist-Led Continuous Glucose Monitoring for Prediabetes: Protocol for a Prospective Cohort Study,' published in JMIR Research Protocols. It is imperative to state immediately that this document outlines a planned research methodology and does not contain any study results, findings, or data regarding the efficacy or safety of the proposed intervention. The abstract explicitly notes that at the time of writing, recruitment is ongoing, no participants have been enrolled, and outcome data are not yet available. Therefore, no conclusions regarding health outcomes, treatments, or interventions can be drawn from this abstract. Full-text verification is strictly required to comprehend the complete methodological framework, the detailed statistical analysis plan, and the specific protocols for participant safety and data management. According to the background information provided by the authors in the abstract, prediabetes is identified as a critical window for intervention to observe the progression to type 2 diabetes. The authors state that the current standard of care involves weight loss and lifestyle modifications. They note that while these approaches are highly effective, they are often limited by adherence in real-world settings. The abstract further asserts that continuous glucose monitoring (CGM) is recognized for improving glycemic and behavioral outcomes in individuals with diabetes; however, the authors note that outcomes among individuals with prediabetes have not been extensively described in the existing literature. Based on this rationale, the stated aim of the planned study is to evaluate the impact of a pharmacist-led continuous glucose monitoring intervention on glycemic control and health-related behaviors specifically in adults diagnosed with prediabetes. The abstract outlines a prospective cohort study design that will be compared against a matched retrospective usual-care cohort. The planned sample size is highly restricted, targeting a total of 40 participants. This total will be divided equally into 20 participants in the prospective continuous glucose monitoring cohort and 20 participants in the retrospective control group. The inclusion criteria for the prospective cohort specify adults between the ages of 18 and 70 years who have a prediabetes diagnosis, defined in this protocol as having a hemoglobin A1c (HbA1c) level between 5.7% and 6.4%. Additionally, prospective participants must possess a compatible smartphone and must not have used continuous glucose monitoring technology in the six months prior to enrollment. The abstract does not detail the specific matching criteria that will be used to select the 20 retrospective control participants, which is a critical methodological detail that requires full-text verification. The planned intervention for the prospective cohort involves the use of a continuous glucose monitor, specifically mentioning the Stelo glucose biosensor by Dexcom. Alongside the device, participants will receive diabetes self-management education and support facilitated by a pharmacist. The duration of this planned intervention is 12 weeks. The abstract does not provide the specific curriculum of the education and support program, nor does it detail the frequency or nature of the interactions with the pharmacist. These are essential variables that necessitate a thorough review of the full-text manuscript. The study protocol designates the change in hemoglobin A1c (HbA1c) at the 12-week mark as the primary outcome measure, which will be compared between the prospective and retrospective groups. Secondary outcomes are planned to include metrics derived from the continuous glucose monitors, changes in scores on the Summary of Diabetes Self-Care Activities (SDSCA) assessment, changes in scores on the 36-Item Short Form Health Survey (SF-36), and any adverse effects related to the use of the continuous glucose monitor. The inclusion of these secondary measures indicates an intention to assess behavioral and quality-of-life variables alongside glycemic data, though the abstract does not specify how these instruments will be administered or analyzed. The abstract provides a clear timeline for the research, noting that the study was funded in 2026. It explicitly states that the study is expected to be completed in July 2027, with results anticipated to be disseminated in December 2027. This timeline reinforces the preliminary nature of the document and confirms the complete absence of current empirical data. The planned study seeks to evaluate the glycemic impact, behavioral changes, and safety of this pharmacist-led approach within a primary care setting. However, due to the small planned sample size (n=40) and the non-randomized, retrospective nature of the control group, any future findings will likely be considered preliminary or exploratory. The abstract concludes with trial registration information (ClinicalTrials.gov NCT07529366). In summary, this abstract provides a structural overview of a future study but offers no clinical evidence, results, or actionable data, underscoring the absolute necessity of full-text verification and cautious interpretation of protocol papers.
Full Analysis
This comprehensive analysis examines the abstract of a study protocol titled 'Pharmacist-Led Continuous Glucose Monitoring for Prediabetes: Protocol for a Prospective Cohort Study,' published in JMIR Research Protocols. It is of paramount importance to establish at the outset of this analysis that the provided text is a protocol paper, not a completed clinical trial or observational study. A study protocol outlines the planned methodology, rationale, and analytical framework for a research endeavor that has not yet yielded data. The abstract explicitly confirms this status by stating that recruitment is ongoing, no participants have been enrolled at the time of writing, and outcome data are not yet available. Consequently, this analysis will focus strictly on evaluating the reported research design, the planned methodological framework, the stated limitations of the proposed approach, and the extensive requirements for full-text verification. No clinical conclusions, efficacy claims, or health recommendations can or should be derived from this document. Background and Rationale as Reported: The abstract begins by contextualizing the planned research within the domain of prediabetes, which the authors describe as a critical intervention window to reduce the progression to type 2 diabetes. The authors state that the current standard of care for prediabetes treatment relies on weight loss and lifestyle modification. The abstract notes that while these interventions are highly effective, they are limited by real-world adherence. To address this stated limitation, the authors introduce continuous glucose monitoring (CGM). The abstract asserts that it is well recognized that CGM improves glycemic and behavioral outcomes in individuals diagnosed with diabetes. However, the authors identify a gap in the literature, noting that outcomes associated with CGM use among people with prediabetes are not well described. Based on this rationale, the stated aim of the planned study is to evaluate the impact of a pharmacist-led CGM intervention on glycemic control and health-related behaviors specifically in adults with prediabetes. Reported Study Design and Methodological Framework: The abstract outlines a non-randomized, dual-cohort study design. Specifically, it describes a prospective pharmacist-led CGM cohort that will be compared against a matched retrospective usual-care cohort. This design choice carries significant methodological implications. A prospective cohort involves enrolling participants and following them forward in time to observe outcomes following an intervention. Conversely, a retrospective cohort relies on historical data from individuals who previously received standard care. While matching attempts to align the characteristics of the retrospective group with the prospective group to isolate the effect of the intervention, this design is inherently more susceptible to confounding variables and selection bias compared to a randomized controlled trial (RCT). The abstract does not detail the specific variables that will be used to match the prospective and retrospective cohorts (e.g., age, baseline BMI, socioeconomic status, baseline HbA1c). Understanding these matching criteria is critical for evaluating the internal validity of the planned study, making full-text verification absolutely essential. Participant Eligibility and Planned Sample Size: The planned study targets a highly restricted sample size of 40 participants in total. This will be divided into 20 participants for the prospective CGM cohort and 20 participants for the retrospective control cohort. A sample size of 40 is generally considered small in clinical research and may significantly limit the statistical power of the study to detect meaningful differences between groups, particularly for secondary behavioral outcomes. The inclusion criteria for the prospective cohort are defined as adults aged 18 to 70 years who have a diagnosis of prediabetes. The abstract quantifies this diagnosis as a hemoglobin A1c (HbA1c) level between 5.7% and 6.4%. Additional eligibility criteria require prospective participants to possess a compatible smartphone (necessary for interfacing with the CGM hardware) and to have no history of CGM use in the six months prior to enrollment. The criteria for selecting the retrospective control records are not provided in the abstract. The Planned Intervention: The intervention planned for the prospective cohort involves the application of a continuous glucose monitor for a duration of 12 weeks. The abstract specifically mentions the 'Stelo glucose biosensor' by Dexcom. In addition to the hardware, the intervention includes 'diabetes self-management education and support' that is described as being 'pharmacist-led.' The abstract provides no further details regarding the nature of this education and support. Crucial elements such as the frequency of contact with the pharmacist, the curriculum of the education provided, the mode of communication (in-person, telehealth, or automated messaging), and the specific behavioral targets of the support are entirely absent from the abstract. Without the full text, it is impossible to determine the intensity or standardizability of the pharmacist-led component of the intervention. Planned Outcome Measures: The protocol defines a clear hierarchy of outcome measures to be assessed at the conclusion of the 12-week intervention period. 1. Primary Outcome: The primary endpoint is designated as the change in hemoglobin A1c (HbA1c) at 12 weeks, which will be compared between the prospective and retrospective groups. HbA1c is a standard biomarker reflecting average blood glucose levels over approximately two to three months, making a 12-week follow-up an appropriate timeframe for this specific metric. 2. Secondary Outcomes: The abstract lists several secondary outcomes, indicating a multidimensional evaluation approach. These include: - CGM-derived metrics: The abstract does not specify which metrics (e.g., Time in Range, Time Above Range, Glucose Management Indicator, or glycemic variability) will be prioritized. - Changes in Summary of Diabetes Self-Care Activities (SDSCA) scores: The SDSCA is a validated self-report questionnaire measuring frequency of self-care activities (e.g., diet, exercise, blood sugar testing). - Changes in 36-Item Short Form Health Survey (SF-36) scores: The SF-36 is a widely used instrument for assessing health-related quality of life across various physical and mental domains. - CGM-related adverse effects: This indicates a planned safety evaluation of the device itself (e.g., skin irritation, sensor failure). Timeline and Current Status: The abstract provides explicit transparency regarding the timeline of the research. It notes that the study was funded in 2026. At the time the abstract was written, recruitment was ongoing, and zero participants had been enrolled. The expected completion date for the study is July 2027, with the dissemination of results anticipated in December 2027. This timeline unequivocally confirms that the document contains no empirical data and serves solely as a declaration of research intent. Inherent Limitations of the Planned Design: Based solely on the information provided in the abstract, several limitations of the planned study design are apparent and must be preserved in any analysis: 1. Lack of Randomization: The use of a retrospective control group rather than a concurrently randomized control group introduces a high risk of unmeasured confounding variables. Changes in standard care practices over time, differences in data recording quality, and selection bias cannot be fully eliminated through matching. 2. Small Sample Size: The planned enrollment of only 40 participants (20 per arm) limits the statistical power of the study. It increases the margin of error and the likelihood of Type II errors (failing to detect a true effect) or exaggerated effect sizes if an effect is observed. 3. Short Duration: A 12-week intervention period is relatively brief for assessing sustained behavioral changes or long-term glycemic trajectories in a prediabetic population. 4. Unblinded Nature: By definition, participants wearing a CGM and receiving pharmacist education cannot be blinded to their intervention, which may introduce performance bias, particularly for self-reported secondary outcomes like the SDSCA and SF-36. Requirements for Full-Text Verification: The abstract of a protocol paper is inherently a high-level summary. Full-text verification is absolutely mandatory to understand the scientific rigor of the proposed study. The full text is required to ascertain: - The exact statistical analysis plan, including how the researchers intend to handle missing data and whether they have conducted a formal power calculation to justify the sample size of 40. - The specific variables and statistical methods (e.g., propensity score matching) that will be utilized to match the retrospective control cohort to the prospective cohort. - The detailed curriculum, frequency, and delivery method of the 'pharmacist-led diabetes self-management education and support.' - The specific CGM metrics that will be analyzed as secondary outcomes. - The protocols for ensuring data privacy and managing the technological requirements (smartphone compatibility) of the intervention. Conclusion: In conclusion, the abstract for 'Pharmacist-Led Continuous Glucose Monitoring for Prediabetes: Protocol for a Prospective Cohort Study' outlines a planned methodological framework for future research. It describes a small (n=40), non-randomized study comparing a 12-week pharmacist-led CGM intervention against a retrospective control group. Because this is a protocol paper, it contains zero data, zero results, and zero clinical findings. The abstract serves to pre-register the researchers' intentions and methodology, enhancing transparency before data collection is complete. However, it provides no evidence regarding the efficacy, safety, or utility of the proposed intervention. Strict adherence to research literacy requires acknowledging that no health implications or practical actions can be drawn from a study protocol. Full-text verification is required to review the complete methodological details, and empirical data will not be available until the study is completed and published, which the authors anticipate will occur in late 2027.Health Implications
This abstract outlines a study protocol and inherently establishes no health outcomes, efficacy data, or safety findings. A study protocol is a document describing the planned methodology for future research. The text explicitly states that no participants have been enrolled and no outcome data are available. The planned study aims to eventually evaluate a 12-week pharmacist-led continuous glucose monitoring intervention in 40 adults with prediabetes, comparing them to a retrospective control group. Because no research has been conducted yet, this document provides no evidence to support or refute the use of continuous glucose monitors or pharmacist-led education for prediabetes management. Readers must exercise strict caution and recognize that protocol papers are published to enhance methodological transparency prior to data collection, not to provide clinical evidence or practical advice. Any understanding of the intervention's potential impact must await the completion of the study, which the authors anticipate in late 2027, followed by peer-reviewed publication of the actual empirical results.
Key Findings
- This is a study protocol; no participants have been enrolled and outcome data are not yet available.
- The planned study aims to evaluate changes in HbA1c and health-related behaviors in 40 adults with prediabetes over 12 weeks.
DOI: 10.2196/105275